BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patie
Go back to BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patie| (NASDAQ: BNTX) | Delayed: 96.06 -2.6 (2.64%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $98.66 | 52 Week High | $ | |||
| Open | $98.81 | 52 Week Low | $ | |||
| Day High | $99.25 | P/E | N/A | |||
| Day Low | $95.71 | EPS | $ | |||
| Volume | 1,195,340 | |||||
